Human leukocyte antigen‑haploidentical donor‑derived cytokine‑induced killer cells are safe and prolong the survival of patients with advanced non‑small cell lung cancer

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2727-2733

  Wang, Shiyong ^a   Zhang, Hui ^a   Liu, Chang ^a   Jiao, Xue ^a   Liu, Dijie ^a   Du, Weili ^a   He, Ying ^a   Zhang, Zhe ^a   Wu, Xiuyan ^a   Wang, Jialing ^a   Liang, Chunyan ^a   Zhang, Lu ^a   Liu, Shu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive; Allogeneic; Carcinoma; Cytokine induced killer cells; Immunotherapy; Malignant tumor; Non small cell lung

Indexed keywords

CD45 ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CYTOKINE INDUCED KILLER CELL; FEMALE; FEVER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE FUNCTION TEST; INSOMNIA; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA AND VOMITING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; VERY ELDERLY;

EID: 84908053585     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2558     Document Type: Article

References (28)

1. Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT and Wu CP: Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 14: 102-108, 2012.
2. Mesiano G, Todorovic M, Gammaitoni L, et al: Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12: 673-684, 2012.
3. Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF and Wang HX: Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14: 483-493, 2012.
4. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P and Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 27: 130-139, 2009.
5. Li R, Wang C, Liu L, et al: Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 61: 2125-2133, 2012.
6. Liu L, Zhang W, Qi X, et al: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 18: 1751-1759, 2012.
7. Wu C, Jiang J, Shi L and Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28: 3997-4002, 2008.
8. Zhong R, Teng J, Han B and Zhong H: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60: 1497-1502, 2011.
9. Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-310, 2011.
10. Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX and Xia JC: Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother 35: 189-195, 2012.
11. Hui D, Qiang L, Jian W, Ti Z and Da-Lu K: A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41: 36-41, 2009.
12. Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2: 363-368, 2011.
13. Wang S, Du W, Zhang H, et al: Biological characteristics and antitumor activity of CIK cells activated by recombinant human fibronectin for human lung cancer cell lines in vitro. Zhongguo Fei Ai Za Zhi 13: 277-281, 2010 (In Chinese).
14. Beasley MB, Brambilla E and Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40: 90-97, 2005.
15. Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest 136: 260-271, 2009.
16. Niu Q, Wang W, Li Y, et al: Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11: 449-456, 2011.
17. Li Y, Schmidt-Wolf IG, Wu YF, et al: Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res 30: 3493-3499, 2010.
18. Laport GG, Sheehan K, Baker J, et al: Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17: 1679-1687, 2011.
19. Zhong ZD, Luo Y, Zou P, et al: Infusions of recipient-derived cytokine-induced killer cells of donor origin eradicated residual disease in a relapsed leukemia patient after allo-hematopoietic stem cell transplantation. Chin Med J (Engl) 125: 1669-1671, 2012.
20. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M and Cignetti A: Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 9: 831-840, 2009.
21. Sangiolo D, Martinuzzi E, Todorovic M, et al: Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 20: 841-848, 2008.
22. Liu C, Wang S, Jiao X, Liu D, Huang W, Ma K and Wang J: Antitumor effect of antigen-pulsed DC-CIK cells against prostate cancer DU145 cells. Progress of Anatomical Sciences 18: 222-226, 2012.
23. Wang QJ, Wang H, Pan K, et al: Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 29: 641-648, 2010.
24. Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62: 65-73, 2013.
25. Tan G, Zhang X, Feng H, Luo H and Wang Z: The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Clin Dev Immunol 2011: 649359-649367, 2011.
26. Wu X, Wang S, Jiao X, et al: The dynamic changes of hTERT expression in long-term cultured CIK cells. J Modern Oncology 20: 667-671, 2012.
27. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420, 2009.
28. Yang B, Lu XC, Yu RL, et al: Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematol Oncol 30: 115-122, 2012.